3 Reasons to Buy CRISPR Therapeutics Stock

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.

The Motley Fool • Jul 10, 2026

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.

Zacks Investment Research • Jul 10, 2026

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

The Motley Fool • Jul 8, 2026

Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now

CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.

The Motley Fool • Jul 7, 2026

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.

Zacks Investment Research • Jul 7, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

The Motley Fool • Jul 7, 2026

Progress Report: How Our Top Stock Picks of 2026 Are Faring

Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.

Schaeffers Research • Jul 7, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

The Motley Fool • Jul 6, 2026

CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices

CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.

FXEmpire • Jul 3, 2026

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.

Seeking Alpha • Jul 3, 2026